Search

Your search keyword '"Van, Gwyneth"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Van, Gwyneth" Remove constraint Author: "Van, Gwyneth"
48 results on '"Van, Gwyneth"'

Search Results

2. RANK Is the Intrinsic Hematopoietic Cell Surface Receptor That Controls Osteoclastogenesis and Regulation of Bone Mass and Calcium Metabolism

7. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

8. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

9. T-cell co-stimulation through B7RP-1 and ICOS

10. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

11. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

12. The Candidate Neuroprotective Agent Artemin Induces Autonomic Neural Dysplasia without Preventing Peripheral Nerve Dysfunction

21. Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N → S (nN → σ*S–X) Interaction for Conformational Constraint

22. Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

23. Correction to Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept

24. Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept

25. Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles

28. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL

29. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies

32. Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses

35. A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage

37. Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts

38. Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function

40. Small Molecule Disruptorsof the Glucokinase–GlucokinaseRegulatory Protein Interaction: 1. Discovery of a Novel Tool Compoundfor in Vivo Proof-of-Concept.

46. A novel Notch ligand, Dll4,induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer

47. Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitroand in Vivo

48. Correction to Small MoleculeDisruptors of the Glucokinase–Glucokinase Regulatory ProteinInteraction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept.

Catalog

Books, media, physical & digital resources